An Clinical Study Evaluating the Safety, Tolerability, and efficAcy of HG005 in StaRgardT Disease | MicrobiomeTrials← Back to trialsNCT07063251
An Clinical Study Evaluating the Safety, Tolerability, and efficAcy of HG005 in StaRgardT Disease
RecruitingEARLY_PHASE1INTERVENTIONAL
Trial Details
Start: 2025-08-20Est. Completion: 2027-02-28
Enrollment target: 6 participants Locations- Eye & ENT Hospital of Fudan University, Shanghai, China
Other microbiome trials you might be interested in
Stargardt Disease
This study evaluates the efficacy and safety of investigational study drug ALK-001 in participants 8 to 45 years of age,…
Phoenix, United StatesEst. completion Oct 2029
Retinal DegenerationRetinitis PigmentosaStargardt's Disease
Background:
Retinal diseases cause the loss of rod and cone photoreceptors. Symptoms include vision loss and night blin…
Bethesda, United StatesEst. completion Dec 30, 2029
Phase 1
Recruiting
The purpose of the 039-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-039…
Phoenix, United StatesEst. completion Jul 2032